3OMK image
Deposition Date 2010-08-27
Release Date 2011-01-19
Last Version Date 2024-04-03
Entry Detail
PDB ID:
3OMK
Title:
Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimidazol-1-yl]-2-cyclohexyl-N-(2-methylphenyl)ethanamide
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
(Taxon ID: )
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.90 Å
R-Value Free:
0.24
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
C 2 2 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Bile acid receptor
Gene (Uniprot):NR1H4
Mutations:E281A, E354A
Chain IDs:A, C
Chain Length:233
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:peptide of Nuclear receptor coactivator 1
Gene (Uniprot):NCOA1
Chain IDs:B, D
Chain Length:14
Number of Molecules:2
Biological Source:
Ligand Molecules
Primary Citation
Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties
Bioorg.Med.Chem.Lett. 21 1134 1140 (2011)
PMID: 21269824 DOI: 10.1016/j.bmcl.2010.12.123

Abstact

Structure-guided lead optimization of recently described benzimidazolyl acetamides addressed the key liabilities of the previous lead compound 1. These efforts culminated in the discovery of 4-{(S)-2-[2-(4-chloro-phenyl)-5,6-difluoro-benzoimidazol-1-yl]-2-cyclohexyl-acetylamino}-3-fluoro-benzoic acid 7g, a highly potent and selective FXR agonist with excellent physicochemical and ADME properties and potent lipid lowering activity after oral administration to LDL receptor deficient mice.

Legend

Protein

Chemical

Disease

Primary Citation of related structures